Cross-Sector entity

Compounding pharmacies

Company
6.5

FDA is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. That works out to roughly 1.8 stories per week across an 8-day span. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category.

2 verified stories tracked

Last mentioned: Aug 1, 2026

Entity pulse

Recent coverage · Compounding pharmacies

2 stories
6.5 avg impact
50% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.

  • 50% positive
  • 50% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Compounding pharmacies

FDA is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. That works out to roughly 1.8 stories per week across an 8-day span. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2.5 original sources each. We currently track 2 Cross-Sector stories that mention Compounding pharmacies, published between July 25, 2026 and August 1, 2026.

Stories tracked
2
Per week
1.8
Sources per story
2.5

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Compounding pharmacies. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Compounding pharmacies 2

Biotech fda approval Neutral 7

Safe Drugs Act targets 100+ compounding pharmacies amid GLP-1 drug demand surge

Biopharma companies watch as the Safe Drugs Act proposes to force large compounding pharmacies under FDA manufacturing standards, potentially curtailing compounded GLP‑1 copies that have capitalized on brand‑name shortages. The regulatory shift could favor innovators like Novo Nordisk and Eli Lilly, reshape the competitive landscape, and alter the risk‑reward calculus for obesity‑focused pipelines.

2 sources

Source: vtcng.com · sanfordherald.com